These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15276728)

  • 1. Pharmaceuticals in the aquatic environment--a comparison of risk assessment strategies.
    Bound JP; Voulvoulis N
    Chemosphere; 2004 Sep; 56(11):1143-55. PubMed ID: 15276728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline.
    Grung M; Källqvist T; Sakshaug S; Skurtveit S; Thomas KV
    Ecotoxicol Environ Saf; 2008 Oct; 71(2):328-40. PubMed ID: 18068226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products.
    Liebig M; Moltmann JF; Knacker T
    Environ Sci Pollut Res Int; 2006 Mar; 13(2):110-9. PubMed ID: 16612900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.
    Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI
    J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial ecological risk assessment of eight selected human pharmaceuticals in Japan.
    Yamamoto H; Nakamura Y; Nakamura Y; Kitani C; Imari T; Sekizawa J; Takao Y; Yamashita N; Hirai N; Oda S; Tatarazako N
    Environ Sci; 2007; 14(4):177-93. PubMed ID: 17762841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly active human pharmaceuticals in aquatic systems: A concept for their identification based on their mode of action.
    Christen V; Hickmann S; Rechenberg B; Fent K
    Aquat Toxicol; 2010 Feb; 96(3):167-81. PubMed ID: 20053463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):67-87. PubMed ID: 16257037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?
    Coetsier CM; Spinelli S; Lin L; Roig B; Touraud E
    Environ Int; 2009 Jul; 35(5):787-92. PubMed ID: 19201471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges.
    Christensen AM; Markussen B; Baun A; Halling-Sørensen B
    Chemosphere; 2009 Oct; 77(3):351-8. PubMed ID: 19682723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress of pharmaceutical and personal care products on ecological and human health].
    Liu Y; Zhu L; Li J
    Wei Sheng Yan Jiu; 2009 Mar; 38(2):237-40. PubMed ID: 19408672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecotoxicology of human pharmaceuticals.
    Fent K; Weston AA; Caminada D
    Aquat Toxicol; 2006 Feb; 76(2):122-59. PubMed ID: 16257063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine, diclofenac, ibuprofen and bezafibrate--investigations on the behaviour of selected pharmaceuticals during wastewater treatment.
    Strenn B; Clara M; Gans O; Kreuzinger N
    Water Sci Technol; 2004; 50(5):269-76. PubMed ID: 15497857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.
    Laenge R; Steger-Hartmann T; Schweinfurth H
    Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of personal care products in the aquatic environment: environmental concentrations and toxicity.
    Brausch JM; Rand GM
    Chemosphere; 2011 Mar; 82(11):1518-32. PubMed ID: 21185057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada.
    Lishman L; Smyth SA; Sarafin K; Kleywegt S; Toito J; Peart T; Lee B; Servos M; Beland M; Seto P
    Sci Total Environ; 2006 Aug; 367(2-3):544-58. PubMed ID: 16697441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
    Pappas G; Ierodiakonou V; Falagas ME
    Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.